- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07749222
Pulmonary Function, Respiratory Muscle Strength, Lung Age, Balance, And Quality Of Life In Paralympic Athletes
Investigation Of Pulmonary Function, Respiratory Muscle Strength, Lung Age, Balance, And Quality Of Life In Paralympic Athletes: A Cross-Sectional Study
Paralympic athletes actively participate in many sports despite their physical limitations and continue to develop both individually and athletically. Assessing the physical and functional capacities of these athletes is important in terms of performance and health. This study aimed to examine the relationships between respiratory function, respiratory muscle strength, lung age, balance, and quality of life in Paralympic athletes. Additionally, it was evaluated whether there were significant differences in these parameters according to disability type and gender.
The study included 24 Paralympic athletes from the disciplines of athletics, swimming, archery, and wheelchair basketball. Participants had various orthopeadic and neurological disability types, including cerebral palsy, lower extremity amputation, spinal cord injuries (C5-T6 and T7 and below), hypotonia, poliomyelitis, spina bifida, brachial plexus injury, and short stature. Respiratory function was assessed using forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), FEV₁/FVC ratio, peak expiratory flow (PEF), and forced expiratory flow (FEF25-75%); respiratory muscle strength was assessed using maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP). Lung age was calculated based on FEV₁ values, balance was measured using the Modified Functional Reach Test, and quality of life was determined using the Short Form (SF-36) questionnaire. Significant correlations were found between parameters. Based on the study results, supporting respiratory muscle strength in Paralympic athletes may be an important goal in rehabilitation and training programs to support respiratory function, lung age, and quality of life parameters.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Istanbul, Turkki (Türkiye)
- İstanbul Okçular Vakfı
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Being between 18-50 years of age
- Being registered with any of the sports federations in Turkey and being a licensed paralympic athlete for at least 1 year (
- Having a lower extremity or upper extremity amputation or having permanent injuries as determined by the International Paralympic Committee
Exclusion Criteria:
- Lack of consent to participate in the study.
- Having undergone surgery within the last 6 months.
- Having had a respiratory tract infection within the three weeks prior to the evaluations
- FEV1/FVC < 0.7
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Forced expiratory volume in the first second (FEV1) (L)
Aikaikkuna: 4 months
|
Pulmonary function (Forced expiratory volume in the first second FEV1)) was evaluated with a portable spirometer, COSMED Pony FX® (COSMED S.r.l., Italy) and measurements were performed according to European Respiratory Society standards. Considering that dizziness may occur during forced expiration, measurements were made while individuals were in a sitting position. While participants were sitting in a comfortable position in a chair with a backrest, nose clip was attached and they were asked to bite the mouth teeth and close their lips in a way that did not allow air to escape. The tests were performed at least 3 times by the participants and care was taken to ensure that the expiration time was at least 6 seconds and the plateau time was 1 second. Due to the device software that records all three data, it saved the average of the two best data and processed it as a value. |
4 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Forced vital capacity (FVC) (L)
Aikaikkuna: 4 months
|
Pulmonary function ((Forced vital capacity (FVC )) was evaluated with a portable spirometer.
|
4 months
|
|
FEV1 / FVC (%)
Aikaikkuna: 4 months
|
Pulmonary function (FEV1 / FVC) was evaluated with a spirometer.
|
4 months
|
|
Peak flow rate (PEF) (L/s)
Aikaikkuna: 4 months
|
Pulmonary function (Peak flow rate (PEF)) was evaluated with a spirometer.
|
4 months
|
|
Flow rate 25-75% of forced expiratory volume (FEF 25-75%) (L/s)
Aikaikkuna: 4 months
|
Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)) was evaluated with a spirometer.
|
4 months
|
|
Maximal expiratory pressure (MEP) (L)
Aikaikkuna: 4 months
|
The MEP which shows respiratory muscle strength was evaluated using a portable mouth pressure measuring device based on European Respiratory Society criteria.
|
4 months
|
|
Maximal inspiratory pressure (MIP) (L)
Aikaikkuna: 4 months
|
The MIP which shows respiratory muscle strength was evaluated using a portable mouth pressure measuring device based on European Respiratory Society criteria.
|
4 months
|
|
Balance
Aikaikkuna: 4 months
|
Balance was measured using the Modified Functional Reach Test
|
4 months
|
|
Quality of Life
Aikaikkuna: 4 months
|
Quality of life was determined using the Short Form-36 (SF-36) Health Survey that contains 36 questions and produces scores for eight health related quality of life domains.
Each domain is transformed to a 0-100 scale.
Higher scores represents better health status while lower stores represents poor health status.
|
4 months
|
|
Lung Age
Aikaikkuna: 4 months
|
Lung age was calculated based on FEV₁ values.
For male: Lung age (years)=(2.87×height in cm×0.394)-(31.25×FEV1 in L)-39.375
For females: Lung age (years)=(3.56×height in cm×0.394)-(40×FEV1 in L)-77.280
|
4 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Morris JF, Temple W. Spirometric "lung age" estimation for motivating smoking cessation. Prev Med. 1985 Sep;14(5):655-62. doi: 10.1016/0091-7435(85)90085-4.
- Pinheiro L, Verhagen E, Ocarino J, Fagher K, Ahmed OH, Dalton K, Mann DL, Weiler R, Akinyi Okoth C, Blauwet CA, Lexell J, Derman W, Webborn N, Silva A, Resende R. Periodic health evaluation in Para athletes: a position statement based on expert consensus. BMJ Open Sport Exerc Med. 2024 Oct 9;10(4):e001946. doi: 10.1136/bmjsem-2024-001946. eCollection 2024.
- Freitas JP, Costa R, Barranco LC, Reis K, Lopes AJ, Mainenti MRM, Dos Santos Vigario P. Effect of inspiratory muscle training on pulmonary function, respiratory muscle strength, aerobic performance, sports skills, and quality of life in wheelchair rugby athletes. J Bodyw Mov Ther. 2024 Oct;40:360-365. doi: 10.1016/j.jbmt.2024.04.049. Epub 2024 Apr 20.
- Fischer G, Tarperi C, George K, Ardigo LP. An exploratory study of respiratory muscle endurance training in high lesion level paraplegic handbike athletes. Clin J Sport Med. 2014 Jan;24(1):69-75. doi: 10.1097/JSM.0000000000000003.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- Paralympic_Athlete
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .